Literature DB >> 24255609

The treatment of acute lymphoblastic leukemia has come a long way but the best is yet to come.

Maria de Lourdes Lopes Ferrari Chauffaille1.   

Abstract

Entities:  

Year:  2013        PMID： 24255609      PMCID： PMC3832306          DOI： 10.5581/1516-8484.20130116

Source DB:  PubMed          Journal:  Rev Bras Hematol Hemoter        ISSN： 1516-8484


× No keyword cloud information.
  4 in total

Review 1.  Treatment of acute lymphoblastic leukemia.

Authors:  Ching-Hon Pui; William E Evans
Journal:  N Engl J Med       Date:  2006-01-12       Impact factor: 91.245

2.  Has MRD monitoring superseded other prognostic factors in adult ALL?

Authors:  Monika Brüggemann; Thorsten Raff; Michael Kneba
Journal:  Blood       Date:  2012-10-02       Impact factor: 22.113

3.  Minimal residual disease in acute lymphoblastic leukemia.

Authors:  Dario Campana
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2010

4.  Gene rearrangement study for minimal residual disease monitoring in children with acute lymphocytic leukemia.

Authors:  Juliana Godoy Assumpção; Francisco Danilo Ferreira Paula; Sandra Guerra Xavier; Mitiko Murao; Joaquim Caetano de Aguirre; Alvaro Pimenta Dutra; Eduardo Ribeiro Lima; Benigna Maria de Oliveira; Marcos Borato Viana
Journal:  Rev Bras Hematol Hemoter       Date:  2013
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.